Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Next Previous
Search
Trial Profile

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacmilimab (Primary) ; Ipilimumab
  • Indications Malignant melanoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms PROCLAIM; PROCLAIM-CX-072-002
  • Sponsors CytomX Therapeutics

    • Most Recent Events

    • 05 Aug 2021 According to a CytomX Therapeutics media release, data from this study published in Journal for ImmunoTherapy of Cancer.
    • 07 Jul 2020 According to a CytomX Therapeutics media release, Rosen Law Firm eminds purchasers of the securities of CytomX Therapeutics between May 17, 2018, and May 13, 2020, inclusive, of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for CytomX investors under the federal securities laws.
    • 07 Jul 2020 According to a CytomX Therapeutics media release, as per the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that, CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program. When the true details entered the market, the lawsuit claims that investors suffered damages.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top